Miranda W. Langendam
- Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolonesBy Giovanni Battista Migliori, Miranda W. Langendam, Lia D'Ambrosio, Rosella Centis, Francesco Blasi, Emma Huitric, Davide Manissero and Marieke J. van der WerfGiovanni Battista Migliori*WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate##These authors contributed equallyMiranda W. Langendam#Dutch Cochrane Centre, Academic Medical Center, University of Amsterdam##These authors contributed equallyLia D'Ambrosio*WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, TradateRosella Centis*WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, TradateFrancesco Blasi¶Respiratory Medicine Section, Dipartimento Toraco-Polmonare e Cardiocircolatorio, University of Milan, IRCCS Fondazione Cà Granda, Milan, ItalyEmma Huitric+European Centre for Disease Prevention and Control (ECDC), Stockholm, SwedenDavide Manissero+European Centre for Disease Prevention and Control (ECDC), Stockholm, SwedenMarieke J. van der Werf§Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, AmsterdamfKNCV Tuberculosis Foundation, The Hague, The Netherlands
- Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysisBy Marieke J. van der Werf, Miranda W. Langendam, Emma Huitric and Davide ManisseroMarieke J. van der Werf*KNCV Tuberculosis Foundation, The Hague#Center for Infection and Immunity Amsterdam (CINIMA)Miranda W. Langendam¶Dutch Cochrane Centre, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsEmma Huitric+European Centre for Disease Prevention and Control (ECDC), Stockholm, SwedenDavide Manissero+European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
- Knowledge of tuberculosis-treatment prescription of health workers: a systematic reviewBy Marieke J. van der Werf, Miranda W. Langendam, Emma Huitric and Davide ManisseroMarieke J. van der Werf*KNCV Tuberculosis Foundation, The Hague#Center for Infection and Immunity Amsterdam (CINIMA)Miranda W. Langendam¶Dutch Cochrane Centre, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsEmma Huitric+European Centre for Disease Prevention and Control (ECDC), Stockholm, SwedenDavide Manissero+European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
- Rational use of tuberculosis drugs to prevent the development of drug resistanceBy Emma Huitric, Marieke J. van der Werf, Miranda W. Langendam, Lia D'Ambrosio, Rosella Centis, Francesco Blasi, G.B. Migliori and Davide ManisseroEmma Huitric1Office of the Chief Scientist, European Centre for Disease Prevention and Control (ECDC), Stockholm, SwedenMarieke J. van der Werf2Unit Knowledge Management, Research, and Policy Development, KNCV Tuberculosis Foundation, The Hague, NetherlandsMiranda W. Langendam3Dutch Cochrane Centre, Academic Medical Center, University of Amsterdam, NetherlandsLia D'Ambrosio4WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, ItalyRosella Centis4WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, ItalyFrancesco Blasi5Respiratory Medicine Section, Dipartimento Toraco-Polmonare e Cardiocircolatorio, University of Milan, IRCCS Fondazione Cà Granda, Milan, ItalyG.B. Migliori4WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, ItalyDavide Manissero1Office of the Chief Scientist, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
- Protecting the TB drug pipeline. Stating the case for the rational use of FluoroquinolonesBy GB Migliori, Miranda W. Langendam, Lia D'Ambrosio, Rosella Centis, Francesco Blasi, Emma Huitric, Davide Manissero and Marieke J. van der WerfArticle | Published in 2012 in European Respiratory JournalGB MiglioriMiranda W. LangendamLia D'AmbrosioRosella CentisFrancesco BlasiEmma HuitricDavide ManisseroMarieke J. van der Werf
- Protecting the TB drug pipeline. Stating the case for the rational use of FluoroquinolonesBy GB Migliori, Miranda W. Langendam, Lia D'Ambrosio, Rosella Centis, Francesco Blasi, Emma Huitric, Davide Manissero and Marieke J. van der WerfArticle | Published in 2012 in European Respiratory JournalGB MiglioriMiranda W. LangendamLia D'AmbrosioRosella CentisFrancesco BlasiEmma HuitricDavide ManisseroMarieke J. van der Werf
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.